Clinical trial
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar…
NCT00117351 · Millennium Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00117351 |
|---|---|
| Title | VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features |
| Official title | A Multicenter, Open-Label, Phase 2 Study of VELCADE (Bortezomib) for Injection in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma With Bronchioloalveolar Features |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar |
| Intervention type | Drug |
| Interventions | VELCADE |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jul 6, 2005 |
| Last update posted | Feb 17, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: